SMRwt
£145.00 1mg
Disrupts the Nef-mortalin interaction, anti-metastatic.
SMRwt is derived from the secretion modification region (SMR, amino acids 66 to 70) of the HIV-1 Nef protein. Nef is a 27-kDa protein produced early during HIV infection of a cell, which interacts with mortalin, a member of the heat shock 70-kDa protein family via Nef’s SMR motif, an interaction which is disrupted by the SMRwt peptide. In breast cancer cells SMRwt interacts with mortalin and also the structural protein vimentin to inhibit pro-epithelial-mesenchymal transition (EMT) exosome release, and induce EMT tumour suppressor protein expression. Exosomes containing EMT programs transmit pro-metastatic phenotypes and SMRwt peptide treatment results in an effective blockade of breast cancer cell migration.
Please contact us for availability.
Additional information
| Other Names | Secretion modification region peptide, SMR peptide, Wildtype-3 |
|---|---|
| Three Letter Sequence | H-Val-Gly-Phe-Pro-Val-Ala-Ala-Val-Gly-Phe-Pro-Val-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-OH |
| Molecular Weight | 2153.03 |
| Molecular Formula | C99H144N22O32 |
| Sequence | VGFPVAAVGFPVDYKDDDDK |
| Solubility | Soluble in water |
| Appearance | Freeze dried solid |
| Storage | Store dry, frozen and in the dark |
| Purity | >95% by HPLC |
| Searchable Words | SMRwt, PP-360, PP360, VGFPVAAVGFPVDYKDDDDK, Secretion modification region peptide, SMR peptide, Wildtype-3 |